EU Clinical Trial 2018-003176-13

Lowering Branched-Chain Amino Acids as a New Strategy to Treat Diabetes  Feb 18, 2019

Main objective of the trial: Primary objective is the delta change in whole body insulin sensitivity expressed as glucose disposal rate (μmol/kg/min) upon 2 weeks of Na-PB vs. placebo treatment.

Parties

Investigators
Sponsors
Countries
FR
Keywords
Pheburane

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.